FMK

FMK is a an irreversible RSK2 kinase inhibitor, that covalently modifies the C-terminal kinase domain of RSK.

Product Specifications

CAS Number

[821794-92-7]

UNSPSC

12352005

Hazard Statement

H302, H315, H319, H335

Target

Ribosomal S6 Kinase (RSK)

Type

Reference compound

Related Pathways

MAPK/ERK Pathway

Applications

Cancer-Kinase/protease

Field of Research

Cancer

Assay Protocol

https://www.medchemexpress.com/FMK.html

Concentration

10mM

Purity

99.83

Solubility

DMSO : 50 mg/mL (ultrasonic)

Smiles

FCC(C1=C(C2=C(N=CN=C2N1CCCO)N)C3=CC=C(C=C3)C)=O

Molecular Formula

C18H19FN4O2

Molecular Weight

342.37

Precautions

H302, H315, H319, H335

References & Citations

[1]Cuello F, et al.  Evidence for direct regulation of myocardial Na+/H+ exchanger isoform 1 phosphorylation and activity by 90-kDa ribosomal S6 kinase (RSK) : effects of the novel and specific RSK inhibitor fmk on responses to alpha1-adrenergic stimulation.|[2]Bain J, et al.  The selectivity of protein kinase inhibitors: a further update. Biochem J. 2007 Dec 15;408 (3) :297-315.|[3]Kang S, et al. FGFR3 activates RSK2 to mediate hematopoietic transformation through tyrosine phosphorylation of RSK2 and activation of the MEK/ERK pathway. Cancer Cell. 2007 Sep;12 (3) :187-9.